Frequency Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Frequency Therapeutics's earnings are forecast to decline at 4.7% per annum. Der Gewinn pro Aktie wird voraussichtlich wachsen um 10.4% pro Jahr.

Wichtige Informationen

-4.7%

Wachstumsrate der Gewinne

10.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	26 Sep 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?

Jan 01

Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?

Jan 19

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are Reducing Their Forecasts For This Year

Aug 18

Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?

Jul 31

Frequency Therapeutics (FREQ) Investor Presentation - Slideshow

Jun 18

Frequency Therapeutics: A Look At What's Next After A Disappointing Data Readout

Apr 21

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are More Bearish Than They Used To Be

Apr 04

We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn

Mar 15

If You Had Bought Frequency Therapeutics (NASDAQ:FREQ) Shares A Year Ago You'd Have Earned 55% Returns

Jan 22

Have Insiders Sold Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Recently?

Dec 27

Frequency Therapeutics to host investor event in early January next year

Dec 18

How Much Are Frequency Therapeutics, Inc. (NASDAQ:FREQ) Insiders Taking Off The Table?

Dec 10

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 19

Frequency Therapeutics EPS beats by $0.16, beats on revenue

Nov 16

Frequency Therapeutics Is An Interesting Speculative Play Ahead Of Phase 2 Results

Nov 09

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:FREQ - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	N/A	-57	N/A	N/A	1
12/31/2024	N/A	-44	N/A	N/A	2
12/31/2023	N/A	-50	N/A	N/A	2
9/30/2023	N/A	-59	-43	-43	N/A
6/30/2023	N/A	-67	-50	-50	N/A
3/31/2023	N/A	-78	-55	-55	N/A
12/31/2022	N/A	-82	-58	-58	N/A
9/30/2022	N/A	-86	-61	-61	N/A
6/30/2022	N/A	-91	-64	-64	N/A
3/31/2022	9	-88	-70	-68	N/A
12/31/2021	14	-85	-79	-76	N/A
9/30/2021	24	-73	-80	-73	N/A
6/30/2021	35	-54	-77	-69	N/A
3/31/2021	34	-42	-68	-61	N/A
12/31/2020	37	-27	-52	-45	N/A
9/30/2020	32	-22	-63	-60	N/A
6/30/2020	45	-18	23	25	N/A
3/31/2020	36	-19	30	31	N/A
12/31/2019	29	-20	33	34	N/A
9/30/2019	24	-20	58	59	N/A
6/30/2019	N/A	-23	-20	-19	N/A
3/31/2019	N/A	-21	-20	-19	N/A
12/31/2018	N/A	-19	-17	-17	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: FREQ wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: FREQ wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: FREQ wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von FREQ schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: FREQ wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von FREQ in 3 Jahren voraussichtlich hoch sein wird

Frequency Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased to US$6.67

Consensus forecasts updated

Price target decreased to US$12.00

Price target increased to US$14.33

Price target decreased to US$12.75

Consensus revenue estimates fall to US$36.2m

Recent updates

Korro Bio, Inc. completed the acquisition of Frequency Therapeutics, Inc. (NasdaqGS:FREQ) from a group of shareholders.

Korro Bio, Inc. completed the acquisition of Frequency Therapeutics, Inc. (NasdaqGS:FREQ) from a group of shareholders.

New major risk - Market cap size

Insufficient new directors

New major risk - Financial position

Frequency Therapeutics, Inc. Announces the Resignation of Christopher Loose as Chief Scientific Officer

New major risk - Share price stability

Korro Bio, Inc. entered into a definitive merger agreement to acquire Frequency Therapeutics, Inc. (NasdaqGS:FREQ) from a group of shareholders in a reverse merger transaction.

Frequency Therapeutics, Inc. Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?

Frequency Therapeutics, Inc. Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss

Price target decreased to US$6.67

Frequency Therapeutics, Inc. Completes Enrollment of Phase 2B Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Frequency Therapeutics, Inc.(NasdaqGS:FREQ) dropped from Russell 2500 Index

Consensus forecasts updated

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Frequency Therapeutics, Inc., Annual General Meeting, Jun 21, 2022

Price target decreased to US$12.00

Insufficient new directors

Frequency Therapeutics, Inc. Announces Peter P. Pfreundschuh Stepping Down as Chief Financial Officer

Price target increased to US$14.33

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?

Insufficient new directors

Frequency Therapeutics, Inc. Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise

Frequency Therapeutics, Inc. Announces New FX-322 Results Showing that Additional Study Participants Gain Hearing Improvements at Later Time Points

Price target decreased to US$12.75

Consensus revenue estimates fall to US$36.2m

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are Reducing Their Forecasts For This Year

Second quarter 2021 earnings released: US$0.52 loss per share (vs US$0.19 loss in 2Q 2020)

Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?

Lieff Cabraser Heimann & Bernstein, LLP Announces That Class Action Litigation Has Been Filed Against Frequency Therapeutics, Inc

Frequency Therapeutics, Inc.(NasdaqGS:FREQ) dropped from Russell 2500 Growth Index

Co-Founder exercised options to buy US$1.1m worth of stock.

Frequency Therapeutics (FREQ) Investor Presentation - Slideshow

Rosen Law Firm Encourages Frequency Therapeutics, Inc. Investors with Losses Exceeding $100,000 to Secure Counsel Before Important Deadline

Price target decreased to US$14.25

Consensus forecasts updated

Forecast to breakeven in 2025

Insider recently bought US$89k worth of stock

Consensus forecasts updated

First quarter 2021 earnings released: US$0.60 loss per share (vs US$0.16 loss in 1Q 2020)

Frequency Therapeutics: A Look At What's Next After A Disappointing Data Readout

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are More Bearish Than They Used To Be

Full year 2020 earnings released: US$0.82 loss per share (vs US$2.29 loss in FY 2019)

Independent Director exercised options to buy US$316k worth of stock.

We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn

Co-­Founder exercised options and sold US$469k worth of stock

Frequency Therapeutics, Inc. Announces Publication of Phase 1/2 Data Showing Hearing Improvements in Acquired Sensorineural Hearing Loss Patients Receiving FX-322

New 90-day high: US$54.87

Frequency Therapeutics, Inc. Appoints Kevin Franck as Senior Vice President of Strategic Marketing and New Product Planning

Co-­Founder exercised options and sold US$385k worth of stock

New 90-day high: US$40.50

If You Had Bought Frequency Therapeutics (NASDAQ:FREQ) Shares A Year Ago You'd Have Earned 55% Returns

Frequency Therapeutics Appoints Quentin McCubbin, Ph.D., as Chief Manufacturing Officer

Co-­Founder exercised options and sold US$594k worth of stock

Have Insiders Sold Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Recently?

Independent Director recently sold US$1.7m worth of stock

Frequency Therapeutics, Inc. Enters into an Agreement for Termination of Lease and Voluntary Surrender of Premises

Frequency Therapeutics to host investor event in early January next year

Price target raised to US$36.33

Co-­Founder exercised options and sold US$437k worth of stock

How Much Are Frequency Therapeutics, Inc. (NASDAQ:FREQ) Insiders Taking Off The Table?

New 90-day high: US$28.86

Frequency Therapeutics Appoints Peter Pfreundschuh as Chief Financial Officer

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Third quarter 2020 earnings released: US$0.16 loss per share

Revenue beats expectations, earnings disappoint

Frequency Therapeutics EPS beats by $0.16, beats on revenue

Co-Founder exercised options and sold US$469k worth of stock

Co-Founder exercised options and sold US$385k worth of stock

Co-Founder exercised options and sold US$594k worth of stock

Co-Founder exercised options and sold US$437k worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock